Vaibhav Sahai, MD
Enriched profileAssociate Professor of Internal Medicine, University of Michigan · University of Michigan
Vaibhav Sahai is Associate Professor of Internal Medicine, University of Michigan at University of Michigan. OpenAlex indexes 644 publications with 11,193 citations (h-index 48); ClinicalTrials.gov lists 13 registered studies with this person as an investigator.
Data verified 22 Oct 2026
Overview
Updated 22 Oct 2026
Vaibhav Sahai, M.D., is Associate Professor of Internal Medicine, University of Michigan. The public record shows 644 publications with 11,193 citations (h-index 48), centered on Pancreatic and Hepatic Oncology Research, Cholangiocarcinoma and Gallbladder Cancer Studies, Fibroblast Growth Factor Research. It also documents an investigator role on 13 registered clinical trials, industry payments reported by 11 companies, 1 NIH-funded awards (2019–2023).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Pancreatic and Hepatic Oncology Research
- 13 registered trials on ClinicalTrials.gov
- Open Payments reporting from 11 companies
Generated from the cited public record · current as of 22 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 34 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 94.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 22 Oct 2026
Listed as an investigator on 13 registered studies on ClinicalTrials.gov. The most recent:
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Sponsor: Verastem, Inc.
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Sponsor: Verastem, Inc.
Industry payments
Updated 22 Oct 2026
11 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20252 payments
- Delcath SystemsProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
50.6%Antidiarrheal microorganisms27.7%Creon69%Zenpep31%Part D<11 patientsSerotonin-3 Receptor Antagonist12.6%Ondansetron Hcl100%Part D≥20 patients+ 1 more class in this area
Nervous system
25.5%Phenothiazine12.1%Prochlorperazine Maleate100%Part D≥19 patientsGabapentinoids6.9%Gabapentin100%Part D<11 patients+ 1 more class in this area
Blood & clotting
17.7%Factor Xa inhibitor17.7%Eliquis100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 22 Oct 2026
1 NIH research award on record, funded 2019–2023 per NIH RePORTER. The latest:
- Targeting the RNA Exosome for Cancer Therapeutics
University of Michigan at Ann Arbor
FY2023$479,616R01CA213214 - Targeting the RNA Exosome for Cancer Therapeutics
University of Michigan at Ann Arbor
FY2022$479,616R01CA213214 - Targeting the RNA Exosome for Cancer Therapeutics
University of Michigan at Ann Arbor
FY2021$489,405R01CA213214
Congress activity
Updated 22 Oct 2026
108 congress contributions (2012–2026) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 4743: Dual inhibition of PIKfyve and FASN reveals therapeutic potential in neuroendocrine prostate cancer
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 22 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- A Phase II Multicenter Trial of Rucaparib and Nivolumab as Maintenance Therapy in Patients with Advanced Biliary Tract Cancer: BilT-02.
Clinical cancer research
Clinical Trial2026 - Real-world analysis of genotype-guided treatment for carriers of actionable DPYD and UGT1A1 variants.
The pharmacogenomics journal
Article2026 - Cobimetinib + Vemurafenib in Patients With BRAF V600E-Mutant Papillary Thyroid and Biliary Tract Cancers: Results From the TAPUR Study.
JCO precision oncology
Clinical Trial2026 - Long-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract Cancers.
JCO precision oncology
Article2026
Most-cited works
by citation count (OpenAlex)- 01
- 02Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyArticle1,004 citations2021
- 03Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancerArticle549 citations2020
- 04
- 05
Network
Updated 22 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 22 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/vaibhav-sahai-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
onclive.com/authors/vaibhav-sahai-mbbs
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 22 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MBBS
MS (name line on the University of Michigan profile; MS reported as a master's in clinical epidemiology from Harvard in a search summary, not seen on the page)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medschool.umich.edu ↗
Editorial & leadership roles
journal and society appointments- Associate Editor
Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers section, Frontiers in Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →frontiersin.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medschool.umich.edu ↗
- Section Head of Gastrointestinal Oncology
Division of Hematology and Oncology, University of Michigan
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uofmhealth.org ↗
Media & interviews
press, podcasts and appearances- OncLive author page listing articles by Vaibhav Sahai
MBBS (interviews and commentary)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pancan.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Max Wicha, MD
University of Michigan
Dinesh Khanna, MD
University of Michigan
Eva Feldman, MD
University of Michigan
Matthias Kretzler, MD
University of Michigan
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH